scholarly journals The Effect of Xuefuzhuyu Oral Liquid on Aspirin Resistance and Its Association with rs5911, rs5787, and rs3842788 Gene Polymorphisms

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Mei Xue ◽  
Lin Yang ◽  
Na Kou ◽  
Yu Miao ◽  
Mingming Wang ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Drug Response ◽  
Blood Stasis ◽  
Chronic Stable Angina ◽  
Coronary Intervention ◽  
Aspirin Resistance ◽  
Blood Stasis Syndrome ◽  
Nucleotide Polymorphisms ◽  
Vascular Events ◽  
Oral Liquid

Aspirin should be continued indefinitely in patients after interventional therapy, but 10% to 40% of patients experience recurrent vascular events despite adequate aspirin therapy, a condition known as aspirin resistance (AR). Xuefuzhuyu oral liquid, derived from the classic recipe Xuefuzhuyu decoction, has been well documented to inhibit platelet aggregation and to improve hemorheology. The aims of this study were to investigate the effects of Xuefuzhuyu oral liquid on AR in patients with chronic stable angina after percutaneous coronary intervention (PCI) and the possible genetic markers related to the drug response. 43 patients diagnosed as having aspirin resistance or semi-resistance were randomly divided into control and treatment groups after screening 207 stable CHD patients. Platelet aggregation rate was determined using turbidimetry. Three single nucleotide polymorphisms in COX-1 (rs5787, rs3842788) and GP IIb (rs5911) were genotyped in whole blood samples using ABI PRISM 7900 HT Fast Real-Time instrument and ABI PRISM 3730 DNA Sequencer. The results showed that Xuefuzhuyu oral liquid could effectively improve blood stasis syndrome and AR by inhibiting ADP-induced platelet aggregation and that patients with the rs5911 genetic variant exhibited better drug response upon treatment with Xuefuzhuyu oral liquid, which suggests Xuefuzhuyu oral liquid as a new possible drug for the prevention of AR.

scholarly journals rs5911 and rs3842788 Genetic Polymorphism, Blood Stasis Syndrome, and Plasma TXB2 and hs-CRP Levels Are Associated with Aspirin Resistance in Chinese Chronic Stable Angina Patients

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Mei Xue ◽  
Xuesong Yang ◽  
Lin Yang ◽  
Na Kou ◽  
Yu Miao ◽  
...  
Keyword(s):  
Genetic Markers ◽  
Stable Angina ◽  
Blood Stasis ◽  
Chronic Stable Angina ◽  
Aspirin Resistance ◽  
Light Transmittance ◽  
Blood Stasis Syndrome ◽  
Hs Crp ◽  
The Impact ◽  
Txb2 Level

The identification of single nucleotide polymorphisms (SNPs) related to aspirin resistance (AR) is of great significance for the explanation why some individuals demonstrate an incomplete response to aspirin and for optimizing the antiplatelet therapy strategy. The study was designed to investigate the possible associated genetic markers and clinical factors of AR for Chinese patients with chronic stable angina after PCI and to analyze the association between TXA2, PGI2, hs-CRP level, AR, and gene polymorphisms. Totally 207 chronic stable angina patients who received 100 mg maintenance dose daily of aspirin for more than 7 days were enrolled. The inhibition of platelets was assessed using light transmittance aggregometry. TXB2, 6-keto-PGF1α, and hs-CRP were measured by radioimmunoassay. Genotyping was performed using Taqman probe technique (rs5787 and rs5911) and gene sequencing technology (rs3842788). By using binary logistic regression analysis, the impact of clinical and genetic determinants on AR was evaluated. The prevalence of AR and aspirin semiresistance (ASR) was 3.86% and 20.76%, respectively, in Chinese chronic stable angina patients. rs5911 A/C and C/C versus A/A genotype (OR = 5.546, 95% CI = 1.812–11.404), rs3842788 A/G versus G/G genotype (OR = 8.358, 95% CI = 2.470–28.286), and blood stasis syndrome (BSS, OR = 10.220, 95% CI = 4.242–24.621) were associated with AR, but rs5787 variants were all homozygous of G/G genotype. Plasma TXB2 and hs-CRP increased significantly in AR and ASR group, while 6-keto-PGF1αshowed no difference, and TXB2 level was significantly higher in carriers of the rs3842788 A/G genotype. According to our results, rs5911 and rs3842788 are proved to be specific genetic markers of AR in Chinese chronic stable angina patients for the first time, and BSS was also proved to be a remarkable determinant for AR. The AR and ASR patients were with increased plasma TXB2 and hs-CRP levels, and the TXB2 level was influenced by the variation of rs3842788 genotype.

scholarly journals Efficacy and safety of Suxiao Jiuxin Pill in the treatment of stable angina (Qi stagnation and blood stasis syndrome): study protocol of a randomized, double-blind, placebo-controlled, multi-center clinical trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Xiaofen Ruan ◽  
Yiping Li ◽  
Yuanlong Sun ◽  
Meijun Jia ◽  
Xiaowen Xu ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Research ◽  
Stable Angina ◽  
Conventional Therapy ◽  
Blood Stasis ◽  
Chronic Stable Angina ◽  
Blood Stasis Syndrome ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Qi Stagnation

Abstract Background Coronary heart disease (CHD) has become one of the biggest health problems in the world. Stable angina is a common clinical type of CHD with poor prognosis and high mortality. Although there are various interventions for stable angina, none of them can significantly reduce mortality. Both basic and clinical research have shown that Suxiao Jiuxin Pill (SJP) can relieve the symptoms of angina pectoris and improve the clinical efficacy, but there is a lack of high-quality clinical research to provide research-based evidence. We design a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of SJP for stable angina. Methods/design This is a prospective, randomized, double-blind, placebo-controlled, and multicenter trial. The trial will enroll 324 participants with chronic stable angina (Qi Stagnation and Blood Stasis syndrome). All participants will have received the conventional therapy of chronic stable angina. Participants will be randomized into two groups, conventional therapy plus SJP group and conventional therapy plus placebo group. Eligible participants will receive either SJP or placebo (five pills administered orally, three times daily) in addition to conventional treatment for 24 weeks. The primary outcomes are the symptom improvement rate of angina from baseline to 4 weeks after inclusion and major adverse cardiovascular events (MACE). The secondary outcomes are angina classification (CCS), improvement of traditional Chinese medicine (TCM) syndromes, Seattle Angina Scale score, the dosage of emergency drugs and the stopping rate, and electrocardiogram (EKG) efficacy. Adverse events will be monitored throughout the trial. Discussion Integrated traditional Chinese and Western Medicine is commonly used for angina in China. This study will evaluate the clinical effectiveness and safety of SJP for angina. The results of the trial will provide high-level clinical research-based evidence for the application of SJP instable angina. Trial registration This study protocol was registered on 14 March 2019. The registration number is ChiCTR1900021876 on the Chinese Clinical Trial Registry.

Abstract 4017: Reduced Anti-Platelet Response to Clopidogrel in Diabetic Patients Undergoing Percutaneous Coronary Intervention

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Jorge Saucedo ◽  
Anand Singla ◽  
Karin Mauer ◽  
Kevin P Bliden ◽  
Mark J Antonino ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Platelet Aggregation ◽  
Light Transmission ◽  
Coronary Intervention ◽  
Platelet Inhibition ◽  
Aspirin Resistance ◽  
Diabetic Patients ◽  
Loading Dose ◽  
Platelet Response ◽  
Percutaneous Coronary

Despite dual antiplatelet therapy with aspirin and clopidogrel, patients with diabetes mellitus (DM) suffer from frequent recurrent ischemic events. Previous studies have shown that DM patients have a higher prevalence of aspirin resistance than non-DM patients. The aim of this analysis was to determine if DM patients have a decreased antiplatelet response to either maintenance or high loading clopidogrel administration when compared to non-DM patients. One hundred and thirty eight patients that underwent percutaneous coronary intervention (PCI) in the Clear Platelets-2 Study were included in this analysis. Patients were grouped according to clopidogrel dose use and presence of DM. Subjects were either on maintenance therapy with 75mg of clopidogrel (C75 group; n=72) or received a loading dose of 600mg of clopidogrel immediately after PCI (C600 group; n=66). All patients received 325-mg aspirin. Platelet function was measured by Light Transmission Aggregometry using ADP (5 and 20μM), TRAP (15 μM), and collagen (2μg/ml). Overall, DM patients in the C75 group had higher platelet aggregation using 5 and 20μM ADP and 2μg/ml collagen. DM patients had lower relative platelet inhibition at 24hrs with 5 μM ADP and 2μg/ml collagen in the C600 group when compared to non-DM patients (Table ). DM patients undergoing PCI exhibit higher platelet aggregation when receiving standard clopidogrel maintenance dose and lower relative platelet inhibition with high clopidogrel loading dose. Higher doses of clopidogrel or more potent P2Y12 receptor antagonists may be needed in DM patients to obtain comparable platelet inhibition to non-DM patients.

Abstract 528: Correlation Between Expression Level of Platelet Endothelial Aggregation Receptor 1 and On-aspirin Platelet Aggregation

2016 ◽  
Vol 36 (suppl_1) ◽  
Author(s):  
Yi Yao ◽  
Jia-Hui Zhang ◽  
Chen He ◽  
Yuan-Liang Ma ◽  
Xiao-Fang Tang ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Transmembrane Protein ◽  
Coronary Intervention ◽  
Interquartile Range ◽  
Expression Level ◽  
Vascular Events ◽  
Increased Risk ◽  
Significant Difference ◽  
Elevated Expression ◽  
Reaction Unit

Background: Aspirin is a basilar support in coronary heart disease secondary prevention, patients with high platelet aggregation during aspirin therapy after percutaneous coronary intervention(PCI) may lead to increased risk of ischemic vascular events. Platelet endothelial aggregation receptor 1(PEAR1) is a platelet transmembrane protein which reported play an important role in platelet aggregation. The aim of the study is to analyze the correlation between PEAR1 expression level and on-aspirin platelet aggregation. Methods: Consecutive patients with acute myocardial infarction after PCI under dual antiplatelet with aspirin and clopidogrel were enrolled in the cohort. Blood samples were obtained 3 days after PCI by peripheral venipuncture. On-aspirin platelet aggregation was assessed by VerifyNow Aspirin Assay, results were recorded as aspirin reaction unit(ARU). Expression of PEAR1 on platelet membrane was determined by washed platelet incubated with mouse anti-human PEAR1 phycoerythrin(PE)-conjugated monoclonal antibody for 20 minutes and analyzed by flow cytometry, results were recorded as mean fluorescence intensity(MFI). Results: A total of 131 patients were enrolled in the study, the average age was 59.88±10.84 years, the average ARU was 443.21±65.99, the median MFI was 137.00(interquartile range 105.00 to 226.00). Patients with high platelet aggregation(ARU>550) showed higher expression of PEAR1 on the surface of platelet than those with low platelet aggregation(ARU<400), although did not achieve a significant difference [129.00(interquartile range 116.75 to 215.75) vs 116.00(interquartile range 86.05 to 197.50), P=0.11]. The expression level of PEAR1 showed a poorly positive correlation with platelet aggregation(Spearman r s =0.21, p=0.02). Conclusion: The study showed that elevated expression of PEAR1 was weakly related to increased on-aspirin platelet aggregation after PCI.

scholarly journals A Systematic Review and Meta-Analysis on the Treatment of Cerebral Hemorrhage with NaoXueShu Oral Liquid

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Lijun Wu ◽  
Yanda Li ◽  
Xiaofeng Wang ◽  
Xiaomeng Ren ◽  
Haiyan Zhu ◽  
...  
Keyword(s):  
Randomized Controlled Trials ◽  
Cerebral Hemorrhage ◽  
Blood Stasis ◽  
Clinical Manifestations ◽  
Acute Stage ◽  
Blood Stasis Syndrome ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Methodologic Quality ◽  
Oral Liquid

NaoXueShu oral liquid invigorates Qi and promotes blood circulation, which is mainly used for treating the acute stage of the meridian of hemorrhagic apoplexy and acute blood stasis syndrome during early convalescence. Its main clinical manifestations include hemiplegia, mouth askew, hemianesthesia, and inarticulateness. It is used mainly in patients with lobar hemorrhage, basal ganglia, and thalamus of the small amount of bleeding without disturbing consciousness of hypertensive cerebral. The purpose of this study was to evaluate the efficacy and adverse effects of NaoXueShu oral liquid on the treatment of cerebral hemorrhage. In this study, literature on randomized controlled trials was collected from seven databases to evaluate the clinical efficiency of the treatment of cerebral hemorrhage alone or combined with Western medicine. The methodologic quality of the included studies was assessed using a standard Cochrane system review and analyzed using RevMan 5.3.0 software. The study included 14 eligible randomized controlled trials. The results showed that the use of NaoXueShu oral liquid alone or combined with other drugs or auxiliary methods can play a significant role in the treatment of cerebral hemorrhage, especially hypertensive intracerebral hemorrhage.

scholarly journals Correlation Analysis between Traditional Chinese Medicine Syndromes and Gastrointestinal Bleeding after Percutaneous Coronary Intervention

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Chenhao Zhang ◽  
Chaolian Huang ◽  
Mingming Wang ◽  
Xiaolin Kong ◽  
Guannan Liu ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Retrospective Study ◽  
Chinese Medicine ◽  
Blood Stasis ◽  
Coronary Intervention ◽  
Deficiency Syndrome ◽  
Blood Stasis Syndrome ◽  
Yin Deficiency ◽  
Percutaneous Coronary ◽  
Heart Blood

Objective. To explore the characters of traditional Chinese medicine (TCM) syndromes after percutaneous coronary intervention (PCI) and to provide syndrome study theoretical evidence for TCM differentiation treatment after PCI through retrospective study. Methods. Patients with coronary heart disease (CHD) who underwent PCI in Cardiovascular Intervention Center of Wangjing Hospital during Dec. 2012 to Dec. 2014 and met the inclusion criteria were enrolled. Retrospective study was then conducted based on patients’ clinical document and angiography data to explore the distribution pattern of TCM syndromes. Results. 801 patients were recruited in the study. TCM syndromes in descending order of their incidence were Qi deficiency and blood stasis syndrome, heart blood stasis syndrome, Qi and Yin deficiency syndrome, phlegm and blood stasis syndrome, Qi stagnation and blood stasis syndrome, Yang asthenia syndrome, heart and kidney yin deficiency syndrome to cold congeal, and blood stasis syndrome in a more to less order. Qi deficiency and blood stasis syndrome was in the most (occurring in 298 patients, 37.20%); Qi and Yin deficiency syndrome occurred in 163 patients (20.35%); heart blood stasis syndrome was shown in 126 patients (15.73%); phlegm and blood stasis syndrome was shown in 95 patients (11.86%). Conclusion. Qi deficiency and blood stasis syndrome was closely associated with post-PCI bleeding, implying that this syndrome might serve as a powerful predictor of GI bleeding as well as a potential supplement to the current predicting and scoring system of bleeding such as CRUSADE.

Sign in / Sign up

Export Citation Format

Share Document